BRUSSELS, BELGIUM--(MARKET WIRE)--Oct 2, 2007 -- Brussels, Belgium and Paris, France, October 2, 2007 - 8:00 am CET - UCB and sanofi-aventis announced today that XYZAL®, a new once-daily medication used to treat indoor and outdoor allergies, as well as chronic idiopathic urticaria, is now available by prescription in the USA. XYZAL® is an oral antihistamine that has been shown to provide powerful allergy symptom relief. XYZAL® is approved for use in adults and children 6 years and older.
